{
    "clinical_study": {
        "@rank": "48582", 
        "arm_group": [
            {
                "arm_group_label": "Reference arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Treated with Reference (bepotastine besilate 10 mg)"
            }, 
            {
                "arm_group_label": "Test arm", 
                "arm_group_type": "Experimental", 
                "description": "Treated with Test (bepotastine salicylate 9.64 mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the relative bioavailability and pharmacokinetic characteristics of a newly\n      developed bepotastine formulation, bepotastine salicylate, with a conventional formulation,\n      bepotastine besilate, in healthy subjects with a single dose, randomized, open-label,\n      2-sequence -2period crossover study."
        }, 
        "brief_title": "PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg", 
        "completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Allergic Rhinitis", 
            "Urticaria", 
            "Pruritus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pruritus", 
                "Rhinitis", 
                "Urticaria"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects aged between 20 and 45 years\n\n          -  Body weight > 50 kg (in case of female > 45 kg) with BMI between 18 and 29 kg/m2\n\n          -  Signed and dated informed consent form which meets all criteria of current FDA and\n             KFDA regulations\n\n        Exclusion Criteria:\n\n          -  subjects with acute conditions.\n\n          -  presence of history affecting ADME\n\n          -  Clinically significant history or current evidence of a hepatic, renal,\n             gastrointestinal, or hematologic abnormality\n\n          -  Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings\n\n          -  Any other acute or chronic disease\n\n          -  A history of hypersensitivity to bepotastine\n\n          -  A history of alcohol or drug abuse\n\n          -  Participation in another clinical trial within 2 months\n\n          -  smoked >10 cigarettes daily\n\n          -  consumption over 5 glasses daily of beverages containing xanthine derivatives\n\n          -  use of any medication having the potential to affect the study results within 10 days\n             before the start of the study.\n\n          -  medication of the inhibitors or inducers of DME including barbiturates within 1 month\n\n          -  one of abnormal lab findings as like\n\n               -  c. AST/ALT > UNL (upper normal limit) x 1.5\n\n               -  Total bilirubin > UNL x 1.5"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897428", 
            "org_study_id": "HL-BPT-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test arm", 
                "intervention_name": "Test-Bepotastine salicylate 9.64 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Berion", 
                    "Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea"
                ]
            }, 
            {
                "arm_group_label": "Reference arm", 
                "intervention_name": "Reference-bepotastine besilate 10 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Tarion", 
                    "Manufactured by Dong-A Pharm. Co., Ltd, Seoul, Korea"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Salicylates"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "136-705"
                }, 
                "name": "Dept. of Clinical Pharmacology & Toxicology, Anam Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Trial to Evaluate Pharmacokinetic Characteristics of Belion in Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "bepotastine pharmacokinetics: peak plasma concentrations (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "24 hr"
            }, 
            {
                "measure": "Bepotastine Pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to 24 hr(AUCall)", 
                "safety_issue": "No", 
                "time_frame": "24 hr"
            }, 
            {
                "measure": "Bepotastine Pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to infinity(AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "24 hr"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897428"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Korea University Anam Hospital", 
            "investigator_full_name": "Ji-Young Park", 
            "investigator_title": "Associate Professor of Clinical Pharmacology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Korea University Anam Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Hanlim Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Korea University Anam Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2011"
    }
}